Morbidity and Mortality of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy: National Cancer Institute, Mexico City, Mexico. (3rd August 2011)

• Record Type: Journal Article
• Authors: López-Basave, Horacio N.; Morales-Vásquez, Flavia; Ruiz Molina, J. M.; González-Enciso, Aaron; Ñamendys-Silva, Silvio A.; Medina Castro, Juan M.; Montalvo-Esquivel, Gonzalo; Herrera-Gómez, Angel; De la Garza Salazar, Jaime G.
• Other Names: Ganesan T. S. Academic Editor.; Kuhnel F. Academic Editor.
• Is Part Of: ISRN oncology. Volume 2011(2011)
• Publication Date: 2011-08-03
• Subjects: Oncology -- Periodicals; Neoplasms; Oncology; Periodicals; 616.994
• DOI: 10.5402/2011/526384
• Languages: English
• ISSNs: 2090-5661

Abstract

Abstract : Peritoneal carcinomatosis (PC) is generally considered a lethal disease, with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a new approach for peritoneal surface disease. This study investigated the early experience with this combined modality treatment at a single institute. From January 2007 to March 2010, 24 patients were treated After aggressive CS, with HIPEC (cisplatin 25 mg/m 2 /L and mitomycin C 3.3 mg/m 2 /L was administered for 90-minutes at 40.5° C). These data suggest that aggressive CRS with HIPEC for the treatment of PC may result in low mortality and acceptable morbidity. Rigorous patient selection, appropriate and prudent operative procedures were associated with encouraging results in our experience.